Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affitech AS

www.affitech.com

Latest From Affitech AS

4-Antibody appoints new CEO

Swiss biopharma company 4-Antibody AG has appointed Dr Robert F Burns as chief executive officer. Dr Burns will drive multi-target pharma collaborations, a key goal for the company following its deal with Boehringer Ingelheim last March, whereby it will develop fully human antibodies for a number of targets in a variety of disease indications. Dr Burns previously served as CEO at both human antibody therapeutics research company Affitech A/S and biotech company Celldex Therapeutics.

Dermatology

Surprise leadership change at Affitech

The Norwegian company Affitech, which recently merged with Pharmexa of Denmark through a reverse acquisition, has made unexpected changes to its leadership through the appointment of Dr Robert Burns as its new chief executive and Dr Alexander Duncan as senior vice-president of R&D.

Dermatology Denmark

Affitech licenses anti-VEGF candidates from partner Peregrine Pharmaceuticals

Affitech has exclusively licensed global rights to develop and commercialise product candidates from Peregrine Pharmaceuticals' preclinical anti-VEGF antibody portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration.

Cancer Norway

Pharmexa and Affitech to merge

Pharmexa is to merge with the private Norwegian company Affitech in an all-stock transaction after several months of failing to find a buyer.

Cancer Germany
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Affitech AS
  • Senior Management
  • Robert Burns, PhD, CEO
    Hans Petter Tjeldflaat, Dir., Fin.
    Michael Braunagel, PhD, Dir., Strategic Alliances & Lic.
    Rathin C Das, PhD, SVP, Corp. Dev.
    Alexander Duncan, PhD, SVP, R&D
  • Contact Info
  • Affitech AS
    Phone: (47) 22 95 87 58
    Gaustadalléen 21
    Oslo, N-0349
    Norway
Advertisement
Advertisement
UsernamePublicRestriction

Register